FogPharma
Latest round
- Series E
Last raised
- Mar 2024
Total raised
- $380M
Investors
- 31
About FogPharma
Based in Massachusetts, US, and founded in 2016, Fog Pharmaceuticals, Inc. operates as a biotechnology company that focuses on developing cell-penetrating miniprotein medicines for the treatment of cancer. The company was founded by its CEO, Greg Verdine. Rowe Price, Farallon Capital Management, VenBio Partners, and Milky Way Ventures. The company provides CPMPs (Cell-penetrating mini proteins) that target cancer-causing proteins inside cancer cells. The CPMPs platform includes Helicons, Pro-locks, and Griptides.
Who invested in FogPharma
31 investors across 5 rounds
See all investors in FogPharma
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about FogPharma
Who invested in FogPharma?
FogPharma has 31 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has FogPharma raised?
FogPharma has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did FogPharma last raise money?
FogPharma's most recent round on record is a Series E, in Mar 2024.
What does FogPharma do?
Based in Massachusetts, US, and founded in 2016, Fog Pharmaceuticals, Inc.
Where is FogPharma headquartered?
FogPharma is headquartered in Cambridge, US.
Which VCs invest in companies like FogPharma?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at FogPharma's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like FogPharma? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.